Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Gets $91 Million Boost, Sequestered User Fees In 2014 Appropriation

This article was originally published in The Tan Sheet

Executive Summary

A 2014 omnibus appropriations bill agreed to by Senate and House appropriators would give FDA $2.55 billion in discretionary funding, a $91 million increase. In news applauded by the device industry, the bill would also make available $85 million in previously sequestered FDA user fees.

You may also be interested in...



Freeing FDA User Fees From Sequestration Proposed Again In Congress

House members again make a bipartisan bid to prevent FDA user fees from being withheld in a potential sequestration as the Obama administration and Congress come to loggerheads over the fiscal 2016 budget.

Freeing FDA User Fees From Sequestration Proposed Again In Congress

House members again make a bipartisan bid to prevent FDA user fees from being withheld in a potential sequestration as the Obama administration and Congress come to loggerheads over the fiscal 2016 budget.

NIH Director Ignores Proposed Funding Based On HHS Goals In Budget Request

Francis Collins tells a House Appropriations subcommittee that a proposed decrease in NIH funding going toward “advancing scientific knowledge and innovation” will not affect how grants and research dollars are allocated.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS107043

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel